Clinical Study Data Request Registered Users, Please Login

Find by:

Study ID:
Medicine:
Phase:

Study to assess the immunogenicity, reactogenicity and safety of GlaxoSmithKline Biologicals’ oral live attenuated human rotavirus (HRV) vaccine following a 0, 2 month schedule, in healthy infants previously uninfected with human rotavirus
Rotavirus Vaccine
103477
NCT00169455
Infections, Rotavirus
Phase 3
 
An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number is not available for this study because the study was conducted before regulatory requirements to register studies.
January 2014

Powered by ideaPoint, Inc.